Dorie Apollonio, PhD

Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoAmerican Legacy Foundation Fellow
    University of California, BerkeleyPhD
    Harvard University, Cambridge, MAMPP
    Macalester College, St. Paul, MNBA

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Linking local variation in marijuana and opioid policies to health outcomes
    NIH R21DA046051Feb 1, 2019 - Jan 31, 2021
    Role: Principal Investigator
    Effects of California’s 2016 tobacco policies on initiation, use, & quitting
    California Tobacco-Related Disease Research Program 26IR-0014Jul 1, 2017 - Jun 30, 2019
    Role: PI
    Measuring combined tobacco, e-cigarette, and marijuana use in California
    California Tobacco-Related Disease Research Program 25IR-0025Nov 1, 2016 - Jun 30, 2019
    Role: Co-PI
    San Francisco Cancer Initiative (SF-CAN)
    UCSF Helen Diller Family Comprehensive Cancer Center Jul 1, 2016 - Jun 30, 2019
    Role: Co-investigator
    Uses of evidence in health policy
    UCSF Research Allocation Program Jul 1, 2015 - Dec 1, 2016
    Role: PI
    State and local policies addressing the use and sale of non-cigarette tobacco products
    NIH/NCI U01 CA 154240Oct 1, 2014 - Sep 3, 2015
    Role: Co-investigator
    Partnership to Advance Breast Cancer Research
    California Breast Cancer Research Program Jan 1, 2014 - Dec 31, 2014
    Role: Co-investigator on subaward
    Translating Research into Systemic Interventions for Tobacco Cessation
    NIH K07CA140236Sep 13, 2011 - Aug 31, 2016
    Role: Principal Investigator
    Creating systemic tobacco control interventions in marginalized populations
    American Cancer Society A114962Jul 1, 2010 - Dec 31, 2011
    Role: PI
    Role Description: Relinquished in Year 2 due to receipt of competing award

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kearns CE, Glantz SA, Apollonio DE. In defense of sugar: a critical analysis of rhetorical strategies used in The Sugar Association's award-winning 1976 public relations campaign. BMC Public Health. 2019 Aug 22; 19(1):1150. PMID: 31438900.
      View in: PubMed
    2. Huey J, Apollonio DE.A review of tobacco policies on University of California campuses. Californian Journal of Health Promotion. 2019; 1(17):24-30.
    3. Pimentel L, Apollonio DE. Placement and sales of tobacco products and nicotine replacement therapy in tobacco-free and tobacco-selling pharmacies in Northern California: an observational study. BMJ Open. 2019 Jun 14; 9(6):e025603. PMID: 31203236.
      View in: PubMed
    4. Apollonio DE, Glantz SA. Tobacco industry promotions and pricing after tax increases: An analysis of internal industry documents. Nicotine Tob Res. 2019 May 06. PMID: 31058282.
      View in: PubMed
    5. Wiltse DL, La Raja RJ, Apollonio DE.Typologies of Party Finance Systems: A Comparative Study of How Countries Regulate Party Finance and Their Institutional Foundations. Election Law Journal. 2019.
    6. Apollonio DE, Spetz J, Schmidt L, Jacobs L, Kaur M, Ramo D. Prevalence and Correlates of Simultaneous and Separate 30-Day Use of Tobacco and Cannabis: Results from the California Adult Tobacco Survey. Subst Use Misuse. 2019; 54(10):1627-1632. PMID: 30973038.
      View in: PubMed
    7. Vijayaraghavan M, Apollonio DE. Engaging Adults Experiencing Homelessness in Smoking Cessation Through Large-Scale Community Service Events. Health Promot Pract. 2019 May; 20(3):325-327. PMID: 30845844.
      View in: PubMed
    8. Apollonio DE, Broyde K, Azzam A, De Guia M, Heilman J, Brock T. Pharmacy students can improve access to quality medicines information by editing Wikipedia articles. BMC Med Educ. 2018 Nov 20; 18(1):265. PMID: 30454046.
      View in: PubMed
    9. Brock T, Apollonio DE. Paving the desire paths of health information needs: Teaching students to edit Wikipedia. BMC Series blog .2018.
    10. Huey J, Apollonio DE. A content analysis of popular media reporting regarding increases in minimum ages of legal access for tobacco. BMC Public Health. 2018 Sep 17; 18(1):1129. PMID: 30223799.
      View in: PubMed
    11. Apollonio DE, Glantz SA. Marketing with tobacco pack onserts: a qualitative analysis of tobacco industry documents. Tob Control. 2018 Jun 28. PMID: 29954860.
      View in: PubMed
    12. Kearns C, Schmidt L, Apollonio D, Glantz S. The sugar industry's influence on policy. Science. 2018 05 04; 360(6388):501. PMID: 29724946.
      View in: PubMed
    13. Tsoh J, Apollonio DE, Hall S, Vijayaraghvan M, Ramo DE, Ling P, Lempert LL, Glantz SA. FDA’s Nicotine Steering Committee should develop policies, regulations, and procedures that promote cessation and increase the use of proven therapies. US FDA Public Comment, Docket FDA-2018-N-0128. .2018.
    14. Apollonio DE, Glantz SA, Hall S, Lempert LL, St.Helen G, Tsoh J. The FDA should not adopt the nicotine “harm reduction” paradigm because doing so is likely to increase the amount of smoking-caused disease and death. US FDA Public Comment, Docket FDA-2017-N-6529. .2018.
    15. Kearns CE, Apollonio D, Glantz SA. Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer: An historical analysis of internal documents. PLoS Biol. 2017 Nov; 15(11):e2003460. PMID: 29161267.
      View in: PubMed
    16. Apollonio D, Glantz SA. Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us". Am J Public Health. 2017 10; 107(10):1636-1642. PMID: 28817320.
      View in: PubMed
    17. Sung H, Apollonio DE. Evaluation of Tobacco Control Policies in San Francisco Homeless Housing Programs. Health Promot Pract. 2017 07; 18(4):571-580. PMID: 28438037.
      View in: PubMed
    18. Apollonio DE, Bero LA. Interpretation and use of evidence in state policymaking: a qualitative analysis. BMJ Open. 2017 02 20; 7(2):e012738. PMID: 28219958.
      View in: PubMed
    19. Gruenberg K, Apollonio DE, MacDougall C, Brock T.Sustainable pharmacy: Piloting a brief curriculum surrounding pharmaceuticals, climate change, and sustainability within a US pharmacy program. Innovations in pharmacy. 2017; 4(8):3.
    20. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016 11 23; 11:CD010274. PMID: 27878808.
      View in: PubMed
    21. Apollonio DE, Wolfe N, Bero LA. Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. BMC Public Health. 2016 08 18; 16(1):822. PMID: 27539238.
      View in: PubMed
    22. Apollonio DE, Bero LA. Challenges to generating evidence-informed policy and the role of systematic reviews and (perceived) conflicts of interest. J Commun Healthc. 2016; 9(2):135-141. PMID: 27721899.
      View in: PubMed
    23. Apollonio DE, Glantz SA. Minimum Ages of Legal Access for Tobacco in the United States From 1863 to 2015. Am J Public Health. 2016 07; 106(7):1200-7. PMID: 27196658.
      View in: PubMed
    24. Krauth D, Apollonio DE. Overview of state policies requiring smoking cessation therapy in psychiatric hospitals and drug abuse treatment centers. Tob Induc Dis. 2015; 13:33. PMID: 26500471; PMCID: PMC4618524.
    25. Krauth D, Apollonio D. Accuracy of popular media reporting on tobacco cessation therapy in substance abuse and mental health populations. BMJ Open. 2015 Mar 26; 5(3):e007169. PMID: 25814498.
      View in: PubMed
    26. Lochner T, Apollonio DE.Karma police: Prosecutorial strategies in obscenity cases and the broader cultural war. Syracuse Law and Civic Engagement Forum. 2015; (2):1-24.
    27. Apollonio DE.Tobacco industry efforts to influence policy: when interest groups face opposition. Interest Group Politics. 2015.
    28. Apollonio DE. Political advocacy in pharmacy: challenges and opportunities. Integr Pharm Res Pract. 2014; 3:89-95. PMID: 26301185.
      View in: PubMed
    29. Lochner T, Apollonio D. Karma Police: Prosecutorial Strategies in Obscenity Cases and the Broader Culture War. Syracuse Law Civ Engagem. 2014; 2. PMID: 28090607.
      View in: PubMed
    30. Apollonio DE, Glantz SA, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5. PMID: 24581055; PMCID: PMC4071941.
    31. Apollonio D, Lochner T, Heddens M. Immigration and Prosecutorial Discretion. Calif J Politics Policy. 2013; 5(2):232-251. PMID: 26146530.
      View in: PubMed
    32. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. Cochrane Libr. 2012 Dec 01; 12:1-10. PMID: 23833567.
      View in: PubMed
    33. Apollonio DE, Malone RE. The "We Card" program: tobacco industry "youth smoking prevention" as industry self-preservation. Am J Public Health. 2010 Jul; 100(7):1188-201. PMID: 20466965.
      View in: PubMed
    34. Apollonio DE.Interest Groups. Developments in American Politics. 2010.
    35. Apollonio DE, Bero LA. Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health. 2009 Jun 17; 9:189. PMID: 19534777; PMCID: PMC2706247.
    36. Apollonio DE, Malone RE. Turning negative into positive: public health mass media campaigns and negative advertising. Health Educ Res. 2009 Jun; 24(3):483-95. PMID: 18948569; PMCID: PMC2682642.
    37. Lochner T, Apollonio DE, Tatum R.Wheat from chaff: Third-party monitoring and FEC enforcement actions. Regulation and governance. 2008; 2(2):216-233.
    38. Apollonio DE, Cain BE, Drutman L.Access and lobbying: Looking beyond the corruption paradigm. Hastings Constitutional Law Quarterly. 2008; 1(36):13-50.
    39. Apollonio DE, Lopipero P, Bero LA. Participation and argument in legislative debate on statewide smoking restrictions. Health Res Policy Syst. 2007 Oct 22; 5:12. PMID: 17953767; PMCID: PMC2174461.
    40. Apollonio DE, Bero LA. The creation of industry front groups: the tobacco industry and "get government off our back". Am J Public Health. 2007 Mar; 97(3):419-27. PMID: 17267719.
      View in: PubMed
    41. Lopipero P, Apollonio DE, Bero LA.Interest groups, lobbying, and deception: The passage of the airline smoking acts. Political science quarterly. 2007; 4(122):635-656.
    42. Apollonio DE, Bero LA.Industry front groups: A tobacco case study. Journal of consumer protection and food safety. 2007; 3(2):341-348.
    43. Apollonio DE, La Raja RJ.Term limits, campaign contributions, and the distribution of power in state legislatures. Legislative studies quarterly. 2006; 2(31):259-281.
    44. Apollonio DE, Malone RE. Marketing to the marginalised: tobacco industry targeting of the homeless and mentally ill. Tob Control. 2005 Dec; 14(6):409-15. PMID: 16319365.
      View in: PubMed
    45. Apollonio DE, Carne MA.Interest group advocacy and the power of ‘magic words’. Election law journal. 2005; 3(4):178-190.
    46. Apollonio DE.Predictors of interest group lobbying decisions. The forum. 2005; 3(3):1-20.
    47. Baldassare MA, Cain BE, Apollonio DE, Cohen JM.The season of our discontent: Voters’ views on California elections. Public Policy Institute of California. 2004.
    48. Apollonio DE, La Raja RJ.Who gave soft money? The effect of interest group resources on political contributions. The journal of politics. 2004; 4(66):1159-1179.
    49. Brady HE, Putnam RD, Campbell AL, Elms LE, Yonish S, Apollonio DE.Roper Social and Political Trends Data (1973-1994). 2000.
    50. La Raja RJ, Apollonio DE.Term limits affect legislators’ fund raising prowess. Public affairs report. 1999; 5(40).
    51. Brady HE, Apollonio DE, Elms LE.Trends in American political participation, 1973-1994. 1998.